Immunization of young African green monkeys with OprF epitope 8–OprI–type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonasaeruginosa
- 1 November 2009
- Vol. 27 (48) , 6762-6769
- https://doi.org/10.1016/j.vaccine.2009.08.080
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- A Fusion Protein Vaccine Containing OprF Epitope 8, OprI, and Type A and B Flagellins Promotes Enhanced Clearance of Nonmucoid Pseudomonas aeruginosaInfection and Immunity, 2009
- Mucosal adjuvant activity of flagellin in aged miceMechanisms of Ageing and Development, 2008
- Protective Immunity toPseudomonas aeruginosaInduced with a Capsid-Modified Adenovirus ExpressingP. aeruginosaOprFJournal of Virology, 2007
- A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patientsProceedings of the National Academy of Sciences, 2007
- Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infectionsProceedings of the National Academy of Sciences, 2007
- Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variationNature, 2002
- Evaluation of Protective mAbs Against Pseudomonas aeruginosa Outer Membrane Protein I by C1q Binding AssayZentralblatt für Bakteriologie, 1991
- Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.Journal of Clinical Investigation, 1989
- Opsonophagocytic Killing Antibody toPseudomonas aeruginosaMucoid Exopolysaccharide in Older Noncolonized Patients with Cystic FibrosisNew England Journal of Medicine, 1987
- Intranasal administration of a Pseudomonas lipopolysaccharide vaccine in cystic fibrosis patientsThe Pediatric Infectious Disease Journal, 1983